FDA and EMA Grant Orphan Drug Designation for Curadel’s CPI-008, a Targeted Zwitterionic Imaging Drug for Pancreatic Cancer
US and EU regulatory designations provide critical development resources to advance novel tumor detection technology
Curadel Pharma Initiates Phase 3 Trial of ZW800-1, a First-in-class Zwitterionic Drug for Optical Surgical Navigation
Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and drugs for optical surgical navigation, announced today that it has initiated the Phase 3 portion of its pivotal study evaluating the investigational ZW800-1 (nizaracianine triflutate) to highlight the ureter during abdominopelvic surgery.
Curadel Pharma secures $10.5M in series A2 funding to propel novel Zwitterionic Radiotherapy Platform
Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and imaging drugs, announced completion of a Series A2 funding round, securing $10.5M to advance early stage development for its lead programs.
Curadel Pharma initiates Phase 2 Portion of the Pivotal trial of ZW800-1, a first-in-class Zwitterionic Ureter imaging surgical drug
Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and imaging drugs, announced the initiation of a pivotal study evaluating its investigational imaging-guided drug ZW800-1 (nizaracianine triflutate) to highlight the ureter during abdominopelvic surgery.